Largest US Stock Movers — October 13, 2026

Session October 13, 2026: the tape split the market into two camps. The gainers were dominated by downstream Energy names - refiners and oilfield services riding crack-spread economics even as crude slipped - plus a rebound in beaten-down consumer and tech-crossover names. The losers were lopsided: a wave of small-cap clinical-stage biotech names and one well-known gene-therapy complex gave back sharply, alongside single-name event damage in media and digital-infrastructure names. Relative volume was extreme in several of the decliners, pointing to news-driven, not drift-driven, selling.

Top Gainers - October 13, 2026 (1-Day Return, Descending)

Symbol	Security Name	Sector	Industry	1D Return	1M Return	6M Return	Market Cap ($B)	Relative Volume	Momentum Potential	P/E (TTM)	Days Since Earnings	% From 52W High	Comments
FRMI	Fermi Inc.	Real Estate	REIT - Specialty	14.46%	-26.34%	-29.55%	2.3855	4.5198	24.6	—	—	-87.60%	Small REIT that has been in freefall all month — this bounce is a dead-cat rally off a deeply depressed base rather than a change in the story. With no recent earnings backdrop, treat the move as positioning in a very thin name.
EFXT	Enerflex Ltd	Energy	Oil & Gas Equipment & Services	14.37%	24.28%	21.84%	2.9479	1.9619	67.1	62.59	68	-2.99%	The cleanest read on the day: energy services leverage to the same downstream margin story lifting the refiners. Multi-year high momentum score signals the trend is being bought, not faded.
EVH	Evolent Health, Inc	Health Care	Health Information Services	8.24%	12.20%	83.27%	0.5201	0.8336	40.7	—	68	-43.77%	Value-based care / specialty health plan manager rebounding hard off a washed-out base. Health-care services names have been the funded side of the sector barbell while clinical-stage biotech gets liquidated.
PARR	Par Pacific Holdings, Inc. Comm	Energy	Oil & Gas Refining & Marketing	8.13%	10.01%	42.08%	4.503	1.1694	89.6	5.27	69	0.00%	Refiner sitting at a fresh 52-week high with a single-digit P/E — crack-spread economics, not crude, are driving the group. Already extended; the risk is chasing into an RSI-75-plus print.
PBF	PBF Energy Inc.	Energy	Oil & Gas Refining & Marketing	7.23%	29.50%	136.47%	10.807	0.9931	36.5	7.99	75	0.00%	Second consecutive month of leadership for the refiners; product margins are carrying the group even as WTI falls. Momentum score is deceptively low for a name at new highs, which suggests the move is still early relative to its cash-flow generation.
CVI	CVR Energy Inc.	Energy	Oil & Gas Refining & Marketing	7.15%	29.80%	110.80%	5.1793	0.7814	41.1	91.48	75	0.00%	Refiner with a hefty-looking trailing multiple that distorts the picture — normalized mid-cycle earnings power is far higher than the headline TTM figure implies. Trades as pure crack-spread beta alongside PBF and PARR.
FWRG	First Watch Restaurant Group, I	Consumer Discretionary	Restaurants	6.93%	5.99%	4.15%	0.743	1.8928	9.7	43	70	-35.48%	Casual dining chain bouncing off its lows, but still far below the 52-week high. Restaurant traffic has been the weak link in consumer discretionary; this looks like a short-covering move rather than a demand inflection.
PTLO	Portillo's Inc.	Consumer Discretionary	Restaurants	6.79%	12.32%	-17.99%	0.3307	2.7764	2.1	25.33	68	-29.85%	Deep-value Chicago-style fast casual with the highest relative volume in the restaurant cohort — something specific is being re-rated here, though the momentum score argues the trend setup is fragile.
GPRE	Green Plains, Inc.	Materials	Chemicals	6.71%	6.64%	1.23%	1.0921	0.9496	33.1	9.33	68	-18.98%	Ethanol producer benefiting from the same energy-complex bid. Margins are commodity-driven and volatile; note the low forward multiple reflects cyclical peak-earnings skepticism, not quality.
QDEL	QuidelOrtho Corporation	Health Care	Medical Devices	6.42%	26.80%	-18.59%	0.9669	1.8589	11.7	—	67	-60.15%	Diagnostics name rebounding after a brutal stretch. Medical devices were the epicenter of the day's health-care selling elsewhere, so this is an idiosyncratic bounce rather than a sector read-through.
BH	Biglari Holdings Inc. Class B Common Stock	Consumer Discretionary	Restaurants	6.16%	6.33%	15.91%	1.2357	0.6005	69.9	—	—	-18.63%	Holding company that trades by appointment — very light relative volume means the move carries little informational weight. The interesting angle is the large discount to the sum of its parts, not the daily tape.
PSIX	Power Solutions International,	Industrials	Specialty Industrial Machinery	6.07%	34.67%	-37.78%	1.2257	0.8891	39.5	18.07	67	-46.20%	Industrial engine and power-generation supplier riding data-center and backup-power demand. The strong monthly trend against a deeply negative six-month figure shows a sharp narrative reset in progress.
LIFE	Ethos Technologies Inc.	Financials	Insurance Brokers	6.02%	0.64%	169.64%	2.574	0.8011	99.8	32.47	70	-5.74%	Insurance brokerage with a very high momentum score and a six-month move that dwarfs anything else in the financials complex. Financials broadly are unloved, which makes this idiosyncratic outperformance notable.
SUPX	SuperX AI Technology Limited - Ordinary Shares	Information Technology	Software - Infrastructure	5.92%	-12.09%	-13.72%	0.3542	0.9732	0.2	—	—	-89.73%	AI-infrastructure small cap with no earnings history — the bounce is a reflex off a nearly 90% drawdown. Speculative positioning; nothing fundamental anchors the price.
NSIT	Insight Enterprises, Inc.	Information Technology	Electronics & Computer Distribution	5.88%	8.67%	151.60%	5.1616	0.7774	85.5	26.02	68	0.00%	IT hardware reseller at a fresh 52-week high with a triple-digit six-month gain. Enterprise hardware refresh and AI server distribution are the tailwind; the risk is that the trade is already consensus.
CNXC	Concentrix Corporation	Information Technology	Information Technology Services	5.85%	-7.89%	-1.76%	1.6474	0.8427	15.8	—	13	-43.35%	Customer-experience outsourcer popping despite a negative monthly trend. Business-process services are being repriced as AI threatens the seat-based model — a bounce here is likely relief, not repair.
GRNT	Granite Ridge Resources, Inc.	Energy	Oil & Gas E&P	5.82%	-0.59%	0.04%	0.6714	0.8544	26.5	28.28	67	-16.69%	Small-cap E&P participating in the broad energy bid. Beta to crude and gas with limited scale; the flat six-month return shows it has gone nowhere while the refiners compounded.
ZURA	Zura Bio Limited - Class A Ordinary shares	Health Care	Biotechnology	5.75%	-18.81%	-26.05%	0.4054	12.9057	21.2	—	63	-39.91%	Clinical-stage biotech bouncing on the highest relative volume of any gainer — almost certainly a data or financing headline. Immaterial to the tape but a reminder that single-asset biotech moves are binary events.
CDW	CDW Corporation	Information Technology	Information Technology Services	5.71%	0.18%	18.12%	18.9989	1.4802	83.2	18.29	69	-4.64%	IT solutions reseller rallying on nearly 1.5x volume, a rare bright spot in a technology complex that saw semiconductor equipment names give back big gains. Scale and a reasonable multiple make it the more defensible end of the hardware trade.
CRSR	Corsair Gaming, Inc.	Information Technology	Computer Hardware	5.68%	9.90%	133.61%	1.4777	0.7262	99.5	46.19	67	-0.21%	Gaming peripherals maker at effectively a new 52-week high after a triple-digit six-month run. Consumer hardware tied to gaming and PC upgrade cycles; the high momentum score says trend traders still own it.
FTK	Flotek Industries, Inc.	Energy	Oil & Gas Equipment & Services	5.54%	2.77%	78.09%	0.9805	0.7536	99.4	26.8	69	-30.27%	Oilfield chemistry specialist with the maximum momentum score, though it remains far below its high. A speculation-grade name in the energy complex rather than a core holding.
VG	Venture Global, Inc.	Energy	Oil & Gas Midstream	5.41%	-9.13%	11.07%	34.6013	0.842	46	10.56	63	-21.05%	LNG exporter rebounding after a rough month. Midstream gas infrastructure has a long-duration growth story tied to global LNG demand — the key swing factor is project execution and contract timing, not the daily barrel.
RERE	ATRenew Inc.	Consumer Discretionary	Internet Retail	5.36%	-0.76%	-17.95%	0.8705	0.3842	13	15.12	54	-38.01%	Chinese electronics-recycling platform — an ADR with very low relative volume, so the move is technically driven. Tradeable only with awareness of both the commodity-refurb cycle and ADR headline risk.
INFY	Infosys Limited	Information Technology	Information Technology Services	5.26%	-1.72%	-16.45%	46.1739	1.3167	11	14.07	82	-43.62%	Indian IT services ADR up sharply after a rough month. The sector is caught between AI-driven deal-model disruption and cheap valuation; a bounce of this size usually reflects a single large deal or guidance headline.
TTMI	TTM Technologies, Inc.	Information Technology	Electronic Components	5.23%	2.54%	-3.84%	12.231	1.4849	41.2	52.3	68	-47.58%	Printed-circuit-board maker tied to defense and data-center demand, yet down sharply over six months — a divergence that suggests expectations were reset hard. Above-average volume confirms conviction behind this bounce.

Top Losers - October 13, 2026 (1-Day Return, Ascending)

Symbol	Security Name	Sector	Industry	1D Return	1M Return	6M Return	Market Cap ($B)	Relative Volume	Momentum Potential	P/E (TTM)	Days Since Earnings	% From 52W High	Comments
ANL	Adlai Nortye Ltd. - American Depositary Shares	Health Care	Biotechnology	-17.33%	-26.21%	-25.03%	0.8823	4.9306	77.4	—	—	-29.19%	Micro-cap biotech ADR with no earnings base and heavy relative volume — a clinical setback or financing event, not a sector move. Liquidity risk is the dominant consideration.
OMDA	Omada Health, Inc.	Health Care	Health Information Services	-16.32%	-10.73%	46.87%	1.1203	2.0014	94.9	27.31	67	-31.67%	The most notable casualty: a digital chronic-care company that had been one of the better six-month performers in health-care services. This is an idiosyncratic hit in a group that had been the funded side of the barbell — the kind of divergence worth checking for guidance or contract news.
SNDX	Syndax Pharmaceuticals, Inc. - Common Stock	Health Care	Biotechnology	-15.71%	-23.98%	-42.90%	1.2457	4.1708	7.1	—	69	-44.53%	Clinical-stage oncology name with elevated volume, extending a steep monthly decline. Additional selling into weakness in developmental biotech is consistent with the broader risk-off in the cohort.
FUN	Six Flags Entertainment Corpora	Consumer Discretionary	Leisure	-14.43%	-22.61%	-49.25%	1.0436	5.7286	4.4	—	68	-61.85%	Amusement-park operator on the largest relative volume in the whole losers table — a leverage-sensitive consumer discretionary name taking a single-name hit while the dollar strengthens and rate-sensitive duration gets repriced lower. Operating leverage cuts both ways.
TSHA	Taysha Gene Therapies, Inc. - Common Stock	Health Care	Biotechnology	-13.53%	-28.54%	-23.99%	1.1665	1.8492	13.8	—	62	-48.71%	Gene-therapy developer sliding further. The gene-therapy complex is tightly correlated on FDA and manufacturing news, so weakness in one name routinely spills over — check for any regulatory read-through.
SLDB	Solid Biosciences Inc. - Common Stock	Health Care	Biotechnology	-13.26%	-33.41%	-29.28%	0.6241	2.5976	18.8	—	67	-47.80%	Another gene-therapy name punished in the same complex-wide move. These companies are perpetually dependent on capital markets, and with high-yield credit softening and long duration repriced lower, the funding window matters more than any single data point.
CIFR	Cipher Digital Inc.	Information Technology	Information Technology Services	-12.77%	-27.47%	-38.54%	4.7064	3.5868	4	—	70	-61.14%	Digital-infrastructure / bitcoin-mining bolt-on taking a double-digit hit on heavy volume. Crypto-linked equities remain among the most fragile cohorts — this selloff coincided with broad weakness in crypto-related ETFs.
PS	Pershing Square Inc.	Financials	Asset Management	-12.12%	19.44%	—	19.06	1.0656	—	—	61	-20.25%	Asset manager declining sharply despite a strongly positive monthly trend — the classic signature of a capital-markets or structure headline rather than a performance issue. Watch share-supply and listing dynamics.
NGNE	Neurogene Inc. - Common Stock	Health Care	Biotechnology	-11.78%	-38.77%	3.85%	0.4314	1.7234	48.5	—	62	-49.67%	Clinical-stage gene therapy name down roughly a fifth over the month. Pre-revenue biotech is being repriced hard as investors withdraw funding for hope; the cohort is the single biggest source of fat left-tail damage in this tape.
GENB	Generate Biomedicines, Inc. - Common Stock	Health Care	Biotechnology	-11.45%	-23.41%	-4.93%	1.573	0.8436	58.3	—	68	-39.87%	Recently public biotech with no trading history to lean on, so price discovery is violent. Index and lock-up mechanics can dominate fundamentals in names this young.
CDNL	Cardinal Infrastructure Group I	Industrials	Engineering & Construction	-10.99%	-44.48%	-62.60%	0.3991	2.9222	12.4	20.69	63	-80.26%	Infrastructure engineering small cap with a staggering six-month decline and a young listing profile. The combination of a recent IPO and a depressed momentum score makes this a momentum-vacuum name.
CBIO	Crescent Biopharma, Inc. - Common Stock	Health Care	Biotechnology	-10.72%	-34.40%	-33.86%	0.4796	0.5337	2.6	—	75	-52.15%	Clinical-stage biopharma in the same broad developmental-medicine drawdown. Capital-intensive pipeline with no revenue to cushion the repricing.
ASMB	Assembly Biosciences, Inc. - Common Stock	Health Care	Biotechnology	-10.67%	-29.77%	-30.91%	0.4141	1.0574	50.2	—	60	-47.17%	Micro-cap antiviral developer with elevated volume — selling in low-float biotech tends to be self-reinforcing when there is no fundamental news to anchor buyers.
BLSM	BlossomHill Therapeutics, Inc. Common Stock	—	—	-10.36%	-28.79%	—	0.492	0.4705	—	—	25	-42.28%	Unclassified recent listing that has yet to establish a sector identity in the data — worth noting because the absence of a fundamental cushion makes the price action entirely flow- and float-driven.
DSGN	Design Therapeutics, Inc. - Common Stock	Health Care	Biotechnology	-10.36%	-27.66%	-22.63%	0.612	1.22	36.1	—	71	-38.64%	Clinical-stage gene-therapy adjacent name, sharply lower over the month. The pattern across this cohort — heavy downside skew, elevated relative volume, no revenue — is what a funding-driven derating looks like.
STTK	Shattuck Labs, Inc. - Common Stock	Health Care	Biotechnology	-9.85%	-11.45%	-19.03%	0.551	1.3693	45.4	—	63	-31.89%	Immuno-oncology developer declining on above-average volume but holding up better than most peers over the month, which is a relative-strength tell if the cohort ever stabilizes.
VSTM	Verastem, Inc. - Common Stock	Health Care	Biotechnology	-9.70%	-0.80%	21.34%	0.6747	1.5024	51.8	—	67	-29.98%	The outlier in the group: one of the only decliners here with a positive six-month return and a reasonable momentum score, meaning this looks like profit-taking or a specific headline rather than a structural break.
PDFS	PDF Solutions, Inc.	Information Technology	Software - Application	-9.62%	11.24%	15.22%	2.0109	1.8103	64.2	190.48	67	-32.73%	Semiconductor yield-analytics software name with a very rich trailing multiple and a positive monthly trend — a valuation-driven pullback in a market that is actively taking money out of the semiconductor capex complex.
SMMT	Summit Therapeutics Inc. - Common Stock	Health Care	Biotechnology	-9.40%	-15.74%	-25.56%	12.3811	1.1568	10.9	—	81	-41.17%	The most prominent biotech decliner by market cap, and the epicenter of the sector's risk-off day. Widely held developmental-stage drug names have been the source of the tape's heaviest left-tail damage for two sessions running.
SGMT	Sagimet Biosciences Inc. - Series A Common Stock	Health Care	Biotechnology	-9.32%	-26.65%	44.04%	0.5659	1.8585	74.2	—	63	-28.56%	Metabolic-disease biotech falling despite a strong six-month run — a give-back of gains rather than a new breakdown, but the cohort correlation means it trades with the group regardless of its own catalyst calendar.
AVTX	Avalo Therapeutics, Inc. - Common Stock	Health Care	Biotechnology	-9.29%	-25.77%	-13.60%	0.6441	1.7726	32.7	—	68	-47.49%	Micro-cap therapeutics name with no revenue and a depressed share price. In this cohort the marginal seller sets the price; there is little valuation support underneath.
ASTS	AST SpaceMobile, Inc. - Class A Common Stock	Information Technology	Communication Equipment	-8.54%	-21.56%	-46.86%	18.3162	1.8674	9.9	—	63	-64.64%	Satellite-to-phone connectivity name far off its high and still sliding. This is a capital-intensive, pre-revenue infrastructure story that is especially exposed to the current repricing of long-duration equity and higher borrowing costs.
ANRO	Alto Neuroscience, Inc. Common Stock	Health Care	Biotechnology	-8.53%	-30.27%	-14.45%	0.8669	1.2985	65.7	—	61	-39.71%	Neuropsychiatry developer with a high momentum score despite the decline — a sign the technical trend was intact before this single-session hit. One to watch for stabilization rather than a broken story.
MPLT	MapLight Therapeutics, Inc. - Common Stock	Health Care	Biotechnology	-8.43%	-40.11%	-70.85%	0.4377	0.3567	3.3	—	60	-80.21%	CNS-focused biotech down roughly 40% over the month. Neurology and rare-disease is one of the worst-performing themes in the book, so the whole subsector is a source of funds right now.
DMRA	Damora Therapeutics, Inc. - Common Stock	Health Care	Biotechnology	-8.37%	-34.62%	-30.56%	1.1458	0.5341	72.1	4.66	63	-45.64%	Clinical-stage biopharma with a high momentum score into this decline and a low float — a profile that can snap back quickly if the selling is positioning rather than a failed readout.

0

What the tape told us

This was a re-ranking tape, not a de-risking tape. The average US stock slipped only modestly, but the distribution of outcomes was badly skewed — roughly 126 names fell 5% or more against about 28 that rose that much. The index masked a wide, sector-specific dispersion.

Gainers: one macro theme, plus a lot of idiosyncratic noise

Three-quarters of the top gainers fell into two buckets:

• Downstream energy. Refiners (PARR, PBF, CVI) and oilfield services (EFXT, FTK) rallied even as WTI fell. That is the crack spread, not the barrel — product margins are driving the group, and integrated oil and gas is the only theme in the book with essentially full participation above its 50-day average. Several of these refiners sit at fresh 52-week highs with single-digit multiples, and momentum scores that are low relative to their cash generation, which says the market still discounts mid-cycle earnings. The risk is simply extension: buying a refiner at RSI 75+ is a different trade than buying one on a pullback to the 50-day.
• Washed-out small caps bouncing off depressed bases. EVH, QDEL, ZURA, SUPX and FRMI are reflex rallies, not repairs. Several carry relative volume far above normal, which for clinical-stage and speculative names usually means a headline — a data readout, a financing, or short covering — rather than a change in fundamentals.

Notably, the gainers also included genuine trend names with real earnings: NSIT at a new high, CDW on strong volume, and CRSR at a 52-week high. These are the more defensible expressions of a technology bid that was, at the index level, under pressure.

Losers: the funding-driven derating of hope

There is no subtlety in the decline column. Health Care is the story, and specifically clinical-stage biotechnology and gene therapy. Roughly two-thirds of the top losers are pre-revenue drug developers (SNDX, TSHA, SLDB, NGNE, GENB, CBIO, ASMB, DSGN, STTK, SGMT, AVTX, ANRO, MPLT, DMRA, ANL) — names with no revenue, no earnings multiple, and an acute dependence on capital markets.

That dependency is the mechanism. Long Treasuries are down over 6% in three months, the dollar has strengthened nearly 4% in a month, and high-yield credit has softened. When the cost of funding future cash flows rises, the longest-duration assets in the equity market — pre-revenue biotech — get repriced first and hardest. This is not a judgment on any individual pipeline; it is a discount-rate event.

The exceptions are informative:

• OMDA was one of the better six-month performers in health-care services before this hit, which suggests a company-specific event rather than a sector move.
• VSTM is the only name in the cohort with a positive six-month return — a give-back, not a breakdown.
• PS, an asset manager, fell double digits despite a strongly positive monthly trend — the signature of a structure or capital-markets headline rather than performance.
• ASTS and CIFR belong to the same duration problem in a different costume: capital-intensive, pre-profit infrastructure stories financed by the capital markets.

Positioning takeaway

The barbell is explicit. Money is on the funded side — energy cash generation, enterprise hardware, health-care services, staples — and it is being taken out of the unfunded side. In that regime, the highest-beta, most idiosyncratically sensitive names get punished faster than the market rewards anything. Note also the concentration of extreme relative volume in the decliners: this was news-driven selling, not slow drift, and news-driven selling in low-float names can overshoot in both directions.

The practical implication is that a single-session mover screen here is mostly a headline detector. The gainers worth attention are the ones with earnings behind them; the losers worth attention are the ones whose decline is idiosyncratic rather than cohort-driven, because those are where the pricing errors are most likely to sit.